SentiSense Logo

SentiSense

Ctrl+K

55% OFF

Quick tip: Press

K

to search stocks

P

PODD

Insulet Corporation

$237.01

-3.93 (-1.63%)

Summary

Stories

News

Metrics

Fundamentals

Current Market Valuation

Current Price

$237.01

Live market price

P/E (TTM)

67.91

EPS: $3.49

P/S (TTM)

6.16

Price to Sales

TTM Quarters

4

Quarters included in TTM

Updated: 3/8/2026, 10:24:21 PM

Historical Trends

Range:

Revenue Over Time

Q1 2021Q2 2022Q3 2023Q4 2025$0B$0B$0B$1B$1B

Net Income Over Time

Q1 2021Q2 2022Q3 2023Q4 2025$-0B$0B$0B$0B$0B

Short Interest (% of Float) Over Time

02/2805/3008/2902/130.0%5.0%10.0%15.0%20.0%High SI

Short Interest

1.5M

% of Float

2.2%

Days to Cover

1.5

Avg Daily Vol

995K

Historical income statement data up to 5 years


Historical SEC Filings

Report Period

Debt/Equity

0.66

Leverage ratio

ROE (TTM)

16.31%

Return on equity

Income Statement

Revenue

$2.71B


Cost of Revenue

$768.20M


Gross Profit

$1.94B


Operating Income

$473.80M


Net Income

$247.10M


EPS (Quarter)

$3.48


EPS (TTM)

--

Balance Sheet

Total Assets

$3.19B


Total Liabilities

$1.68B


Shareholders' Equity

$1.52B


Current Assets

$1.91B


Current Liabilities

$680.10M


Cash & Equivalents

--


Long-Term Debt

--

Cash Flow

Operating Cash Flow

$569.30M


Investing Cash Flow

$-222.70M


Financing Cash Flow

$-595.30M


Free Cash Flow

$346.60M

Profitability Margins

Gross Margin

71.63%

Operating Margin

17.50%

Net Profit Margin

9.12%


ROA (TTM)

7.75%


ROE (TTM)

16.31%

Data source: Polygon.io

Last updated: 3/8/2026, 10:24:21 PM

Company Profile

Symbol

PODD


Market Cap

$16.68B


IPO Date

May 15, 2007


CEO

--


Employees

5,400


Sector

--


Industry

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS


Country

United States


Exchange

--

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Read More
SentiSense Logo

SentiSense

Sense what the market is doing.

© 2026 Compass AI Data Services, LLC. All rights reserved.


Important Disclaimer: Compass AI Data Services, LLC provides market information, sentiment analysis, and data intelligence. We do not provide investment advice, recommendations, or financial guidance. All information is for informational purposes only. Users are solely responsible for their own investment decisions. Always consult a licensed financial advisor before making investment decisions.

Cookie Preferences

We use cookies to enhance your experience and analyze site traffic. Privacy Policy